EU Medtechs Keep Open Mind On HTA Options In Wider Market Access Plan
Executive Summary
Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.
You may also be interested in...
UK Outlook 2018: All To Play For In Technology Adoption With AAR Set For Take Off
Navigating the UK medtech innovation landscape is a notoriously complicated exercise, so industry is hoping the recently released Accelerated Access Review will have positive outcomes as 2018 unfolds. Andrew Davies, market access director for the Association of British Healthcare Industries, says a simplified system of market access for medtech would bring benefits across the board.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.